Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast- enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: A systematic review and cost-effectiveness analysis

Health Technology Assessment

Volumn 17, Issue 16, 2013, Pages 7-243

  Westwood, M ^a   Joore, M ^b   Grutters, J ^c   Redekop, K ^d   Armstrong, N ^a   Lee, K ^a   Gloy, V ^e   Raatz, H ^e   Misso, K ^a   Severens, J ^d   Kleijnen, J ^c  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOXETIC ACID; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; SONOVUE; SUPERPARAMAGNETIC IRON OXIDE; CONTRAST AGENT BR1; CONTRAST MEDIUM; PHOSPHOLIPID; SULFUR HEXAFLUORIDE;

ARTICLE; CANCER PROGNOSIS; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; CRYOSURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; DISEASE SURVEILLANCE; ECHOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOCAL LIVER LESION; HUMAN; INCIDENTAL FINDING; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER METASTASIS; LIVER NODULE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SYSTEMATIC REVIEW; TREATMENT PLANNING; ULTRASOUND SCANNER; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DIAGNOSTIC USE; ECONOMICS; LIVER; LIVER NEOPLASMS; METASTASIS; MICROBUBBLE; PATHOLOGY; RADIOGRAPHY;

CONTRAST MEDIA; COST-BENEFIT ANALYSIS; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICROBUBBLES; NEOPLASM METASTASIS; PHOSPHOLIPIDS; QUALITY-ADJUSTED LIFE YEARS; SULFUR HEXAFLUORIDE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84877302083     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17160     Document Type: Article

References (110)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
2. Ryder S, Hepatocellular UK Group. UK Guidelines for the management of suspected hepatocellular carcinoma (HCC) in adults (revised edition). Nottingham: Nottingham University Hospitals NHS Trust; 2009.
3. Office for National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 1999, England (Series MB1 no. 30). London: ONS; 2002.
4. Cancer Research UK. Cancer incidence for common cancers - UK statistics. London: Cancer Research UK; 2011. URL: http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/ (accessed 14 September 2011).
5. Cabassa P, Bipat S, Longaretti L, Morone M, Maroldi R. Liver metastases: sulphur hexafluorideenhanced ultrasonography for lesion detection: a systematic review. Ultrasound Med Biol 2010;36:1561-7.
6. Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS): update 2008. Ultraschall Med 2008;29:28-44.
7. Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006;32:1369-75.
8. Ward J, Guthrie JA, Scott DJ, Atchley J, Wilson D, Davies MH, et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000;216:154-62.
9. Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology 2005;237:520-8.
10. Lee NK, Kim S, Lee JW, Lee SH, Kang DH, Kim GH, et al. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics 2009;29:1707-24.
11. Guang Y, Xie L, Ding H, Cai A, Huang Y. Diagnosis value of focal liver lesions with SonoVueenhanced ultrasound compared with contrast-enhanced computed tomography and contrastenhanced MRI: a meta-analysis. J Cancer Res Clin Oncol 2011;137:1595-605.
12. Schwartz J, Kruskal J. Approach to the patient with a focal liver lesion. In Basow D, editor. UpToDate. Waltham, MA: UpToDate; 2011.
13. European Association for the Study Of The Liver; European Organisation for Research and Treatment of Cancer, Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
14. National Institute for Health and Care Excellence. Colorectal cancer: the diagnosis and management of colorectal cancer. Full guideline. London: NICE; 2011. URL: www.nice.org.uk/nicemedia/live/13597/56957/56957.pdf (accessed 23 January 2012).
15. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006;55(Suppl. 3):iii1-8.
16. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. York: University of York; 2009. URL: www.york.ac.uk/inst/crd/systematic_reviews_book.htm (accessed 7 June 2011).
17. National Institute for Health and Care Excellence. Diagnostics Assessment Programme: interim methods statement (version 2). London: NICE; 2010. URL: www.nice.org.uk/media/164/3C/DAPInterimMethodsStatementProgramme.pdf (accessed 12 January 2011).
18. The Cochrane Collaboration, Diagnostic Test Accuracy Working Group. Handbook for DTA reviews; 2011. URL: http://srdta.cochrane.org/handbook-dta-reviews (accessed 12 January 2011).
19. Westwood M, Al M, Burgers L, Redekop W, Lhachimi S, Armstrong N, et al. Computed tomography (CT) scanners for cardiac imaging - Somatom Definition Flash, Aquilion One, Brilliance iCT and Discovery CT750 HD. Diagnostic Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Care Excellence. York: Kleijnen Systematic Reviews Ltd; 2011. URL: http://guidance.nice.org.uk/nicemedia/live/13243/56230/56230.pdf (accessed 14 September 2011).
20. Whiting P, Westwood M, Beynon R, Burke M, Sterne JA, Glanville J. Inclusion of methodological filters in searches for diagnostic test accuracy studies misses relevant studies. J Clin Epidemiol 2011;64:602-7.
21. McGowan J, Sampson M, Lefebvre C. An evidence based checklist for the peer review of electronic search strategies (PRESS EBC). Evid Based Libr Inf Pract 2010;5:1-6.
22. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
23. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. A systematic review of sources of variation and bias in studies of diagnostic accuracy. Ann Intern Med 2004;140:189-202.
24. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. A systematic review finds that diagnostic reviews fail to incorporate quality despite available tools. J Clin Epidemiol 2005;58:1-12.
25. Whiting P, Rutjes AW, Westwood M, Mallet S, Deeks JJ, Reitsma JB, et al. The development of QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
26. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org/ (accessed 23 March 2011).
27. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PMM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90.
28. Harbord RM, Deek JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007;8:239-51.
29. Harbord RM, Whiting P, Sterne JA, Egger M, Deeks JJ, Shang A, et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008;61:1095-103.
30. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.
31. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
32. Bohata S, Pavlik T, Chlumska D, Valek V. [Contribution of the contrast enhanced ultrasound in the differential diagnosis of the focal lesions.] Ceska Radiol 2010;64:11-19.
33. Chen M-H, Wu W, Yang W, Gao W, Dai Y, Yin S-S, et al. [Application of contrast-enhanced ultrasonography in selecting indication of radiofrequency ablation among hepatocellular carcinoma patients.] Zhonghua Yi Xue Za Zhi 2005;85:3491-4.
34. Passamonti M, Vercelli A, Azzaretti A, Rodolico G, Calliada F. Characterization of focal liver lesions with a new ultrasound contrast agent using continuous low acoustic power imaging: comparison with contrast enhanced spiral CT. Radiol Med 2005;109:358-69.
35. Banghui P, Chiche L, Alkofer B, Salame E, Bouvard N, Lepennec V. Imaging modalities before liver resection for colorectal metastases: which, when and how many? Paper presented at the 9th World Congress of the International Hepato-Pancreato-Biliary Association, Buenos Aires, Argentina, 18-22 April 2010. HPB 2010;12(Suppl. 1):100.
36. Ercolani G, Zanello M, Rojas L, Ravaioli M, Cescon M, Gaudio MD, et al. A prospective comparative evaluation of pre- and intraoperative imaging techniques in chemo-pretreated or not pretreated patients with colorectal liver metastases. Paper presented at the 9th Congress of the European- African HPBA (E-AHPBA), Cape Town, South Africa, 12-16 April 2011. HPB 2011;13:25-6.
37. Loria F, Loria G, Frosina L, Crea G, Basile S, Cantoni S. Metastatic disease of the liver: comparison of CEUS vs. US and CT in the evaluation of diagnostic performance and confidence. Paper presented at the 9th World Congress of the International Hepato-Pancreato-Biliary Association, Buenos Aires, Argentina, 18-22 April 2010. HPB 2010;12(Suppl. 1):269.
38. Kono Y, Alton K, Rose SC, Hassanein TI, Mattrey RF. The ability of contrast-enhanced ultrasound (CEUS) to predict final outcome within 1 week after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Hepatology 2004;40:706-7A.
39. Flor N, Serantoni S, Barbosa Da Silva F, Impellizzeri E, Danaro M, Cornalba G, et al. Characterization of small indeterminate focal liver lesions at multiphasic MDCT in patients with known primary cancer: US and contrast-enhanced ultrasound as problem-solving approach? Abstract B-582. Paper presented at the European Congress of Radiology, Vienna, Austria, 6-10 March 2009.
40. Lüttich A, Puig J, Martín J, Darnell A, Malet A, Veintemillas M. Can the response to radiofrequency ablation of hepatocarcinoma be adequately measured by means of contrast-enhanced US and dynamic MRI? Abstract B-736. Paper presented at the European Congress of Radiology, Vienna, Austria, 3-7 March 2006.
41. Solbiati L. D-55: Diagnostic performance and cost-effectiveness of contrast-enhanced ultrasound in the characterization of focal liver lesions. Abstract D-55. Paper presented at the European Congress of Radiology, 3-7 March, Vienna, Austria, 2006.
42. Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010;105:599-609.
43. Dai Y, Chen MH, Fan ZH, Yan K, Yin SS, Zhang XP. Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography. Hepatol Res 2008;38:281-90.
44. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104.
45. Giorgio A, De Stefano G, Coppola C, Ferraioli G, Esposito V, Di Sarno A, et al. Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Res 2007;27:4263-9.
46. Quaia E, Alaimo V, Baratella E, Medeot A, Midiri M, Cova MA. The added diagnostic value of 64-row multidetector CT combined with contrast-enhanced US in the evaluation of hepatocellular nodule vascularity: implications in the diagnosis of malignancy in patients with liver cirrhosis. Eur Radiol 2009;19:651-63.
47. Sangiovanni A, Manini MA, Lavarone M, Romeo R, Forzenigo LV, Fraquelli M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638-44.
48. Blondin D, Erhardt A, Crynen K, Sagir A, Scherer A, Kropil P, et al. [Diagnosis of focal liver lesions in cirrhotic patients: comparison of contrast-enhanced ultrasound using sulphur hexafluoride (SF6) microbubbles and MRI using Gd-EOB-DTPA.] Z Gastroenterol 2011;49:23-9.
49. Mainenti PP, Mancini M, Mainolfi C, Camera L, Maurea S, Manchia A, et al. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom Imaging 2010;35:511-21.
50. Jonas E, Nilsson H, Larsson J, Freedman J. Detection of colorectal cancer liver metastases: an assessment of four imaging modalities. Paper presented at the 9th Congress of the EuropeanAfrican HPBA (E-AHPBA), Cape Town, South Africa, 12-16 April 2011. HPB 2011;13:24.
51. Clevert DA, Jung EM, Stock KF, Weckbach S, Feuerbach S, Reiser M, et al. Evaluation of malignant liver tumors: biphasic MS-CT versus quantitative contrast harmonic imaging ultrasound. Z Gastroenterol 2009;47:1195-202.
52. Catala V, Nicolau C, Vilana R, Pages M, Bianchi L, Sanchez M, et al. Characterization of focal liver lesions: comparative study of contrast-enhanced ultrasound versus spiral computed tomography. Eur Radiol 2007;17:1066-73.
53. Gierblinski IW, Wocial T, Jarosz D. [In which cases can contrast-enhanced ultrasound replace fine needle aspiration biopsy? Clinical feasibility study.] Nowotwory 2008;58:238-45.
54. Li R, Guo Y, Hua X, He Y, Ding J, Guo A, et al. Characterization of focal liver lesions: comparison of pulse-inversion harmonic contrast-enhanced sonography with contrast-enhanced CT. J Clin Ultrasound 2007;35:109-17.
55. Seitz K, Strobel D, Bernatik T, Blank W, Friedrich-Rust M, Herbay AV, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilaändertreffen 2008, Davos. Ultraschall Med 2009;30:383-9.
56. Seitz K, Bernatik T, Strobel D, Blank W, Friedrich-Rust M, Strunk H, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM multicenter trial): CEUS vs. MRI - a prospective comparison in 269 patients. Ultraschall Med 2010;31:492-9.
57. Feng XY, Sun XY, Tan BB, Qian GJ, Wu MC. [Evaluation of enhanced ultrasonography for hepatic carcinoma with cryosurgery.] J Interv Radiol 2007;16:246-8.
58. Zhou P, Liu X-Y, Li R-Z, Nie W-P, Liu S. [Comparison of treatment response in primary hepatocellular carcinomas with contrast-enhanced ultrasonography and contrast-enhanced helical CT.] Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007;32:690-4.
59. Chen MH, Wu W, Yang W, Dai Y, Gao W, Yin SS, et al. The use of contrast-enhanced ultrasonography in the selection of patients with hepatocellular carcinoma for radio frequency ablation therapy. J Ultrasound Med 2007;26:1055-63.
60. Chen MH, Yang W, Yan K, Dai Y, Wu W, Fan ZH, et al. The role of contrast-enhanced ultrasound in planning treatment protocols for hepatocellular carcinoma before radiofrequency ablation. Clin Radiol 2007;62:752-60.
61. Sangiovanni A, Manini MA, Romeo R, Iavarone M, Fraquelli M, Forzenigo LV, et al. Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients. Hepatology 2007;46:241-2A.
62. Cokkinos DD, Blomley MJ, Harvey CJ, Lim A, Cunningham C, Cosgrove DO. Can contrast-enhanced ultrasonography characterize focal liver lesions and differentiate between benign and malignant, thus providing a one-stop imaging service for patients? J Ultrasound 2007;10:186-93.
63. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83.
64. Faccioli N, D'Onofrio M, Comai A, Cugini C. Contrast-enhanced ultrasonography in the characterization of benign focal liver lesions: activity-based cost analysis. Radiol Med 2007;112:810-20.
65. Gruppo di lavoro misto SIRM-SNR. IMS; Sago S.p.A Metodologia di determinazione dei volume di attivita e della produttivita dei medici radiologi. Nomenclature SIRM-SNR delle prestazioni radiologiche, Tav III; 2006. p.15.
66. Romanini L, Passamonti M, Aiani L, Cabassa P, Raieli G, Montermini I, et al. Economic assessment of contrast-enhanced ultrasonography for evaluation of focal liver lesions: a multicentre Italian experience. Eur Radiol 2007;17(Suppl. 6):F99-106.
67. Şirli R, Sporea I, Martie A, Popescu A, Danila M. Contrast enhanced ultrasound in focal liver lesions: a cost efficiency study. Med Ultrason 2010;12:280-5.
68. Zaim R, Taimr P, Redekop W, Uyl-de Groot C. Economic evaluation of contrast-enhanced ultrasound (CEUS) in the characterization of focal liver lesions (FLL) in the Netherlands. Rotterdam, Netherlands: Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University; Department of Gastroenterology and Hepatology, Erasmus MC University Hospital; 2011.
69. Dutch Health Care Insurance Board: Farmacotherapeutisch Kompas. URL: www.fk.cvz.nl/ (accessed October 2012).
70. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007;11(34).
71. Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess 2011;15(35).
72. Bennett GL, Krinsky GA, Abitbol RJ, Kim SY, Theise ND, Teperman LW. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR Am J Roentgenol 2002;179:75-80.
73. Roberts SE, Goldacre MJ, Yeates D. Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut 2005;54:1615-21.
74. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77-82.
75. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
76. Office for National Statistics. Mortality statistics: deaths registered in England and Wales (Series DR), 2010. Newport: ONS; 2011. URL: www.ons.gov.uk/ons/rel/vsob1/mortality-statistics--deathsregistered-in-england-and-wales--series-dr-/2010/index.html (accessed 5 January 2012).
77. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97:2886-95.
78. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50.
79. Taouli B, Goh JS, Lu Y, Qayyum A, Yeh BM, Merriman RB, et al. Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr 2005;29:425-9.
80. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5.
81. UK Transplant. Liver transplant services: donor organ use - protocols and guidelines for adults undergoing cadaveric liver transplantation. Bristol: UK Transplant; 2005. URL: www.uktransplant.org.uk/ukt/about_transplants/organ_allocation/liver/national_protocols_and_guidelines/protocols_and_guidelines/adults.jsp (accessed 23 January 2012).
82. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-40.
83. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005;92:1862-8.
84. Department of Health. NHS reference costs 2009-2010. London: Department of Health; 2011. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459 (accessed 5 January 2012).
85. Personal Social Services Research Unit. Unit costs of health and social care. Canterbury: University of Kent; 2011. URL: www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf (accessed 17 January 2012).
86. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-8.
87. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002;8:263-70.
88. Saunders TH, Mendes Ribeiro HK, Gleeson FV. New techniques for imaging colorectal cancer: the use of MRI, PET and radioimmunoscintigraphy for primary staging and follow-up. Br Med Bull 2002;64:81-99.
89. Lejeune C, Bismuth MJ, Conroy T, Zanni C, Bey P, Bedenne L, et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 2005;46:2020-8.
90. Medical Services Advisory Committee. Positron emission tomography for recurrent colorectal cancer. MSAC reference 35a. Assessment report. Canberra, Australia: MSAC; August 2007. URL: www.msac.gov.au/internet/msac/publishing.nsf/Content/8FD1D98FE64C8A2FCA2575AD0082FD8F/$File/MSAC35a_PET_CRC_print250608new.pdf (accessed 5 January 2012).
91. American Cancer Society. Colorectal cancer: facts and figures. Special edition. Atlanta, GA: American Cancer Society; 2005. URL: www.cancer.org/acs/groups/content/@nho/documents/document/caff2005cr4pwsecuredpdf.pdf (accessed 5 January 2012).
92. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. Colon and rectum. In AJCC cancer staging manual, 7th edn. New York, NY: Springer; 2009. pp. 143-64.
93. Office for National Statistics. UK interim life tables, 1980-82 to 2008-10. Newport: ONS; 2011. URL: www.ons.gov.uk/ons/taxonomy/index.html?nscl=Life+Tables (accessed 5 January 2012).
94. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244:254-9.
95. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 58, September 2009. London: BMA and RPS; 2009.
96. Information Services Division, NHS National Services Scotland. Costs book 2009. Edinburgh: NHS National Services Scotland; 2009. URL: www.isdscotlandarchive.scot.nhs.uk/isd/6480.html (accessed 20 November 2009).
97. Cancer Research UK. Treating bowel cancer. URL: http://cancerhelp.cancerresearchuk.org/type/bowel-cancer/treatment/ (accessed 5 January 2012).
98. Guest JF, Ruiz FJ, Greener MJ, Trotman IF. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care 2006;15:65-73.
99. Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000;88:1294-303.
100. Langenhoff BS, Krabbe PF, Peerenboom L, Wobbes T, Ruers TJ. Quality of life after surgical treatment of colorectal liver metastases. Br J Surg 2006;93:1007-14.
101. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637.
102. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. CHE Discussion Paper 172. York: Centre for Health Economics, University of York; 1999. URL: www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf (accessed 5 January 2012).
103. Bartolotta TV, Taibbi A, Midiri M, Matranga D, Solbiati L, Lagalla R. Indeterminate focal liver lesions incidentally discovered at gray-scale US: role of contrast-enhanced sonography. Invest Radiol 2011;46:106-15.
104. Xie L, Guang Y, Ding H, Cai A, Huang Y. Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis. Ultrasound Med Biol 2011;37:854-61.
105. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-93.
106. Cantisani V, Ricci P, Erturk M, Pagliara E, Drudi F, Calliada F, et al. Detection of hepatic metastases from colorectal cancer: prospective evaluation of gray scale US versus SonoVue low mechanical index real time-enhanced US as compared with multidetector-CT or Gd-BOPTA-MRI. Ultraschall Med 2010;31:500-5.
107. Zhou X, McClish D, Obuchowski N. Statistical methods in diagnostic medicine. New York, NY: Wiley Interscience; 2002.
108. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-4.
109. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003;138:W1-12.
110. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995;22:983-93.